Mesalazine induced interstitial pneumonitis in the COVID era.

Abstract

Mesalazine is the most widely used aminosalicylate for induction and maintenance of remission in patients with mild-to-moderate ulcerative colitis (UC). Drug-induced hypersensitivity pneumonitis is considered very rare (<1/10.000 patients). Due to its rarity and the scarce cases reported, mesalazine-induced lung injury needs to be highly suspected in a patient with onset of respiratory symptoms and UC under treatment with salicylates. It should make the clinician formulate a differential diagnosis that includes not only infections (tuberculosis, bacterial...) or the inflammatory bowel disease itself, but also the current coronavirus disease 2019 (COVID-19) since their clinical and radiological manifestations may be very similar.

• Authors: Ana Aparicio Serrano, Elma Gallego Jiménez, Javier Castro Rodríguez, Pilar Soto Escribano, Eva Iglesias Flores, Sandra Marín Pedrosa, José Manuel Benítez
• Journal: Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva (Rev Esp Enferm Dig) Vol. 114 Issue 7 Pg. 429-430 (07 2022) ISSN: 1130-0108 [Print] Spain
• PMID: 35199533 (Publication Type: Letter)

Chemical References

• Anti-Inflammatory Agents, Non-Steroidal
• Mesalamine

Topics

• Anti-Inflammatory Agents, Non-Steroidal (adverse effects)
• COVID-19
• Colitis, Ulcerative (drug therapy)
• Humans
• Lung Diseases, Interstitial (chemically induced, diagnostic imaging, drug therapy)
• Mesalamine (adverse effects)